TRAK — ReposiTrak, Inc.

Summary of ReposiTrak's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q2 revenue increased by 7% to $5.9 million, up from $5.5 million. Year-to-date revenue rose 8% to $11.8 million.
• Operating Expenses: Total operating expenses decreased by 2% to $4.1 million for Q2, remaining flat at $8.1 million year-to-date.
• Income from Operations: Increased 34% to $1.8 million in Q2, with a year-to-date increase of 31% to $3.7 million.
• Net Income: GAAP net income for Q2 was $1.7 million (up 9% YoY), and net income to common shareholders rose 13% to $1.6 million. Year-to-date net income increased 9% to $3.5 million.
• Earnings Per Share (EPS): Q2 EPS was $0.09 (basic and diluted), reflecting a 13% increase YoY. Year-to-date EPS was $0.19 (basic) and $0.18 (diluted).
• Cash Position: Total cash increased slightly to $28.7 million, with no bank debt.

2. Strategic Updates and Business Highlights

• Transition to SaaS: Successfully converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue.
• Debt Reduction: Paid off over $6 million in bank debt since 2020, reducing annual operating expenses from $19 million to $16 million.
• Investment in Innovation: Focused on three key initiatives: enhancing product offerings, filing for two new patents related to Touchless Traceability, and investing in AI and software systems to improve operational efficiency.
• Traceability Network: The ReposiTrak Traceability Network (RTN) is positioned as an industry leader, with a growing queue of suppliers wanting to join.

3. Forward Guidance and Outlook

• Traceability Demand: Anticipates increased demand for Traceability solutions as the FDA's deadline approaches, expecting a surge in onboarding and interest.
• Operational Efficiency: The company expects continued growth in contribution margin as incremental revenue increasingly falls to the bottom line, with no significant increase in cash expenses or capital expenditures anticipated.
• Shareholder Returns: Plans to continue returning 50% of annual cash from operations to shareholders while maintaining a strong cash position.

4. Challenges and Points of Concern

• Data Quality Issues: High error rates (50%-70%) in supplier data pose significant challenges for Traceability, complicating the onboarding process and affecting supply chain integrity.
• Market Competition: The rise of AI tools may lead some companies to underestimate the complexity of Traceability, potentially impacting ReposiTrak's market position.
• Economic Pressures: Food inflation could indirectly affect business as supermarkets face margin squeezes, leading them to scrutinize costs, including those associated with ReposiTrak's services.

5. Notable Q&A Insights

• Traceability Revenue: Traceability currently accounts for approximately 8% to 10% of total revenue, with ongoing cross-selling efforts.
• AI's Role: AI enhances data accuracy in Traceability, but ReposiTrak's approach goes beyond traditional AI models, focusing on error detection and correction.
• Impact of MAHA: Increased public awareness of food safety issues (e.g., MAHA and organic trends) could benefit ReposiTrak by heightening demand for Traceability solutions.
• Ingredient-Level Traceability: The company is capable of tracking ingredients at a detailed level, which may become increasingly important as consumer demand for transparency grows.
• M&A Strategy: While open to acquisitions, the focus remains on current business initiatives, particularly as the FDA deadline approaches, which could create a surge in demand for Traceability solutions.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of ReposiTrak's performance and outlook for Q2 2026.